Home / Psoriasis (page 23)


Here you will find the latest clinical research on psoriasis.

Pediatric psoriasis may have a distinct presentation

Pediatric psoriasis

Children may have a distinctive presentation of psoriasis, compared with adults, Dr. Wynnis Tom said at a pediatric dermatology meeting sponsored by Rady Children’s Hospital–San Diego and UC San Diego School of Medicine. Infants may present with diaper involvement, also known as “napkin psoriasis,” which may be confused with irritant …

Read More »

Healthcare Expenditures of Psoriasis Examined

Psoriasis healthcare costs

In 2012, the top 10% (T10) of psoriasis patients accounted for nearly 40% of overall healthcare expenditures among enrollees with psoriasis in a US health plan, a recent study found. Researchers conducted a retrospective study of patients with psoriasis with continuous enrollment in a plan from January 1, 2011, to …

Read More »

Risankizumab tops ustekinumab in phase II psoriasis trial

Psoriasis treatment

Key clinical point: Clinical responses in psoriasis patients treated with risankizumab were superior to responses in patients treated with ustekinumab. Major finding: At 12 weeks, 77% of risankizumab patients showed a 90% or greater reduction in PASI score, compared with 40% of ustekinumab patients. Data source: A phase II randomized …

Read More »

What’s old is new in topical psoriasis therapy

psoriasis therapy

Key clinical point: A fixed combination of halobetasol and tazarotene formulated as a lotion proved successful in phase II and is now being evaluated in a large phase III study. Major finding: An investigational fixed-combination lotion consisting of halobetasol propionate 0.01% and tazarotene 0.045% achieved scores of clear or almost …

Read More »

$790M Deal Reached For Potential Psoriasis Treatment, AST-005

AST-005 Purdue

Purdue Pharma and Exicure have announced a strategic research alliance and licensing agreement for AST-005, a potential treatment for psoriasis and other diseases amenable to a gene regulation approach by Exicure called spherical nucleic acid (SNA) technology. Purdue will own full global rights to AST-005, among other collaboration targets. Together with …

Read More »